VIVUS Announces ADA Scientific Presentations

VIVUS Announces ADA Scientific Presentations

MOUNTAIN VIEW, Calif., June 21, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc.
(Nasdaq:VVUS), a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity and
sexual health, today announced the following scientific presentations:

Conference

ADA 2013: American Diabetes Association 73^rd Scientific Sessions

June 21-25, 2013

McCormick Place Convention Center (West Building), Chicago, IL

Date/Time

Poster Presentation Date: Sunday, June 23^th, 2013 from 12:00 to 2:00 PM

Session Location: Poster Hall, McCormick Place Convention Center

Poster Number: 2133-P

Presentation Title

Contributions of Percent and Absolute Weight Loss to Improvements in Fasting
Glucose and Insulin Sensitivity

Authors: W. Timothy Garvey, MD^a; Wesley W. Day, PhD^b

Affiliations: ^aUniversity of Alabama at Birmingham, Birmingham, AL;  ^bVIVUS,
Inc., Mountain View, CA

Conference

ADA 2013: American Diabetes Association 73^rd Scientific Sessions

June 21-25, 2013

McCormick Place Convention Center (West Building), Chicago, IL

Date/Time

Guided Poster Presentation Tour: Saturday, June 22^nd, 2013 from 11:30 AM
12:30 PM

Poster Presentation Date: Sunday, June 23^th, 2013 from 12:00 to 2:00 PM

Session Location: Poster Hall, McCormick Place Convention Center

Poster Number: 2103-P

Presentation Title

Weight Loss With Phentermine and Topiramate Extended-Release and Changes in
Glycemic Parameters in Overweight and Obese Adults With Dysglycemia and
Stratified by Baseline Body-Mass Index

Authors: Donna H. Ryan, MD^a; Charles H. Bowden, MD^b

Affiliations: ^aPennington Biomedical Research Center, Baton Rouge, Louisiana;
^bVIVUS, Inc., Mountain View, California

Conference

ADA 2013: American Diabetes Association 73^rd Scientific Sessions

June 21-25, 2013

McCormick Place Convention Center (West Building), Chicago, IL

Date/Time

Poster Presentation Date: Sunday, June 23^th, 2013 from 12:00 to 2:00 PM

Session Location: Poster Hall, McCormick Place Convention Center

Poster Number: 2121-P

Presentation Title

Changes in Glycemic Parameters and Antidiabetic Medication Use by Degree of
Weight Loss With Lifestyle Modification and Phentermine/Topiramate
Extended-Release

Authors: Robert Kushner, MD^a; Barbara Troupin, MD^b

Affiliations: ^aNorthwestern University Feinberg School of Medicine, Chicago,
Illinois; ^bVIVUS, Inc., Mountain View, California

About Qsymia

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet
and increased physical activity for chronic weight management in adults with
an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or
greater (overweight) in the presence of at least one weight-related medical
condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been
established. The safety and effectiveness of Qsymia in combination with other
products intended for weight loss, including prescription and over-the-counter
drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is
contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism;
in patients receiving treatment or within 14 days following treatment with
monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive ingredients in
Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a
negative pregnancy test before treatment and monthly thereafter and use
effective contraception consistently during Qsymia therapy. If a patient
becomes pregnant while taking Qsymia, treatment should be discontinued
immediately, and the patient should be informed of the potential hazard to the
fetus.

The most commonly observed side effects in controlled clinical studies, 5% or
greater and at least 1.5 times placebo, include paraesthesia, dizziness,
dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing
innovative, next-generation therapies to address unmet needs in obesity and
sexual health. For more information about the company, please visit
www.vivus.com.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should," among
others. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. VIVUS does
not undertake an obligation to update or revise any forward-looking
statements. Investors should read the risk factors set forth in VIVUS's Form
10-K for the year ending December 31, 2012, as amended by the Form 10-K/A
filed on April 30, 2013 and by the Form 10-K/A filed on June 12, 2013, and
periodic reports filed with the Securities and Exchange Commission.

CONTACT: VIVUS, Inc.
         Dana B. Shinbaum
         Corporate Development
         & Investor Relations
         shinbaum@vivus.com
        
         Investor Relations:
         The Trout Group
         Brian Korb
         bkorb@troutgroup.com
         646-378-2923
 
Press spacebar to pause and continue. Press esc to stop.